Enrolling adolescents in disease/target-appropriate adult oncology clinical trials of investigational agents

Clinical Cancer Research

Volumn 23, Issue 1, 2017, Pages 9-12

  Chuk, Meredith K ^a   Mulugeta, Yeruk ^a   Roth Cline, Michelle ^a   Mehrotra, Nitin ^a   Reaman, Gregory H ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; NEW DRUG; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANCER RESEARCH; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; HEALTH CARE ACCESS; HUMAN; MALIGNANT NEOPLASM; OFF LABEL DRUG USE; RESEARCH ETHICS; RESEARCH SUBJECT; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; AGE; ETHICS; PATIENT SELECTION; STANDARDS;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; PATIENT SELECTION;

EID: 85010038642     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1367     Document Type: Article

References (27)

1. Tai E, Buchanan N, Westervelt L, Elimam D, Lawvere S. Treatment setting, clinical trial enrollment, and subsequent outcomes among adolescents with cancer: a literature review. Pediatrics 2014;133 Suppl 3:S91-7.
2. Bleyer WA, Tejeda H, Murphy SB, Robison LL, Ross JA, Pollock BH, et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health 1997;21:366-73.
3. Newburger PE, Elfenbein DS, Boxer LA. Adolescents with cancer: access to clinical trials and age-appropriate care. Curr Opin Pediatr 2002;14:1-4.
4. Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 2006;107(7 Suppl):1645-55.
5. Bleyer A, Morgan S, Barr R. Proceedings of a workshop: bridging the gap in care and addressing participation in clinical trials. Cancer 2006;107(7 Suppl):1656-8.
6. Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer 2005;103:1891-7.
7. Tai E, Beaupin L, Bleyer A. Clinical trial enrollment among adolescents with cancer: supplement overview. Pediatrics 2014;133 Suppl 3:S85-90.
8. Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer 2014;120:2497-506.
9. Smith AW, Seibel NL, Lewis DR, Albritton KH, Blair DF, Blanke CD, et al. Next steps for adolescent and young adult oncology workshop: an update on progress and recommendations for the future. Cancer 2016;122:988-99.
10. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 2008;8:288-98.
11. Momper JD, Mulugeta Y, Green DJ, Karesh A, Krudys KM, Sachs HC, et al. Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007. JAMA Pediatr 2013;167:926-32.
12. Lee DP, Skolnik JM, Adamson PC. Pediatric phase I trials in oncology: an analysis of study conduct efficiency. J Clin Oncol 2005;23:8431-41.
13. Paoletti X, Geoerger B, Doz F, Baruchel A, Lokiec F, Le Tourneau C. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials. Eur J Cancer 2013;49:2392-402.
14. Holford N, Heo YA, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci 2013;102:2941-52.
15. Barbour AM, Fossler MJ, Barrett J. Practical considerations for dose selection in pediatric patients to ensure target exposure requirements. AAPS J 2014;16:749-55.
16. Leeder JS, Kearns GL, Spielberg SP, van den Anker J. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 2010;50:1377-87.
17. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67.
18. Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther 2013;137:225-47.
19. Zhang Y, Wei X, Bajaj G, Barrett JS, Meibohm B, Joshi A, et al. Challenges and considerations for development of therapeutic proteins in pediatric patients. J Clin Pharmacol 2015;55 Suppl 3:S103-15.
20. Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 2010;28:4790-9.
21. Weiss AR, Nichols CR, Freyer DR. Enhancing adolescent and young adult oncology research within the National Clinical Trials Network: rationale, progress, and emerging strategies. Semin Oncol 2015;42:740-7.
22. Gupta AA, Indelicato DJ. Increasing the number of clinical trials available to adolescents diagnosed with cancer. Pediatrics 2014;133 Suppl 3:S114-8.
23. Tai E, Buchanan N, Eliman D, Westervelt L, Beaupin L, Lawvere S, et al. Understanding and addressing the lack of clinical trial enrollment among adolescents with cancer. Pediatrics 2014;133 Suppl 3:S98-S103.
24. Leighton JK, Saber H, Reaman G, Pazdur R. An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs. Regul Toxicol Pharmacol 2016;79:142-3
25. U.S. Food and Drug Administration. Guidance for industry: S9 nonclinical evaluation for anticancer pharmaceuticals; 2010. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm085389.pdf.
26. Fern LA, Whelan JS. Recruitment of adolescents and young adults to cancer clinical trials-international comparisons, barriers, and implications. Semin Oncol 2010;37:e1-8.
27. Fern LA, Lewandowski JA, Coxon KM, Whelan J, National Cancer Research Institute Teenage and Young Adult Clinical Studies Group UK. Available, accessible, aware, appropriate, and acceptable: a strategy to improve participation of teenagers and young adults in cancer trials. Lancet Oncol 2014;15:e341-50.